Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

6 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

QRX, QRXPHARMA LTD
nipper
post Posted: May 8 2021, 09:59 AM
  Quote Post


Posts: 9,156
Thanks: 2750


In Reply To: mme's post @ May 13 2014, 10:48 AM

speeding ticket? blew up the gearbox.

... delisted from the commencement of trading on Wednesday, 23 May 2018 pursuant to Listing rule 17.12
QUOTE
Shareholders in this company should consider crystallising a capital loss in 2020/21 by selling their worthless shares, which they can achieve online by entering transaction details here. While this usually makes good economic sense, we recommend you seek professional advice before buying or selling securities,





--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
mme
post Posted: May 13 2014, 10:48 AM
  Quote Post


Posts: 8,077
Thanks: 429


In Reply To: krisbarry's post @ May 13 2014, 08:38 AM

Certainly picked it! Well done. Wait for the speeding ticket! biggrin.gif

 
krisbarry
post Posted: May 13 2014, 08:38 AM
  Quote Post


Posts: 37
Thanks: 1


In Reply To: daggie's post @ May 12 2014, 04:41 PM

Mr. market will give you all the reasons in the world to buy QRX today. Watch the oversold rally continue today with confidence as buy signals have now been triggered.



--------------------
NCR
 
daggie
post Posted: May 12 2014, 04:41 PM
  Quote Post


Posts: 960
Thanks: 12


In Reply To: krisbarry's post @ May 12 2014, 12:43 PM

Please Krisb. give me one good, single reason why do you expect QRX to rally.

 
krisbarry
post Posted: May 12 2014, 12:43 PM
  Quote Post


Posts: 37
Thanks: 1


Major rally on QRX today, check it out



--------------------
NCR
 
krisbarry
post Posted: May 12 2014, 07:13 AM
  Quote Post


Posts: 37
Thanks: 1


QRX is now primed and ready for a major rally off its low. Please I am begging you watch QRX today, its about to rally hard



--------------------
NCR
 


krisbarry1
post Posted: May 9 2014, 02:07 PM
  Quote Post


Posts: 637
Thanks: 3


Extremely Oversold, time to load up for a major rally

 
nipper
post Posted: Mar 12 2013, 12:37 PM
  Quote Post


Posts: 9,156
Thanks: 2750


(sorry about that)

QUOTE
Biotech QRxPharma ((QRX)) has sparked speculative interest this year, given the potential for a positive review of a New Drug Application with the US Food and Drug Administration. Brokers are keenly aware that a go-ahead from the US authority for the MoxDuo IR oxycodone-morphine combination could be a game changer for the stock.

QRX has resubmitted the NDA including the results of Study 022, as requested by the FDA. This extra data shows that the product, for relief of severe pain, could lower the rate of respiratory depression in patients compared with morphine or oxycodone alone. The advantage of MoxDuo IR (immediate release) is that its pain relieving qualities have less side effects than those commonly associated with morphine and oxycodone. These include respiratory depression, constipation, nausea, vomiting and somnolence.

In Citi's view, all the data so far revealed supports the efficacy of the product and there is no reason to suspect MoxDuo IR should not gain approval. Moreover, there are no unexpected toxicity or adverse safety issues reported. Since June 2012, QRX has disclosed more information about the effect of MoxDuo IR against opioid-induced respiratory depression, showing it cuts the incidence of the serious side effect substantially.

Only 55% of drug applications are approved on first application to the FDA, another 20% gain approval after a re-submission and another 8% after a second re-submission, according to Bell Potter. So, the chances remain quite good for success with the re-submission. What pleases Bell Potter is that QRX has a significant licensing deal ready to go for MoxDuo IR with Actavis, a major generic drug company. Actavis would be able to bring substantial marketing power to the drug in the US.

QRX expects to file MoxDuo IR for regulatory review in Canada, Europe and Australia by mid year. Citi notes the possibility the company could announce a European strategic/commercial partnership prior to filing. The broker believes skewing any deal terms to upfront cash payments versus long-term royalties would be preferable. Bell Potter assumes that QRX's average royalties on net sales of MoxDuo IR in the US would start at 10% and gradually converge on 20% by year 10, as more of the Actavis sales reach higher thresholds.

Bell Potter assumes, with the successful re-submission, that all of QRX's three MoxDuo products, IR, IV and CR can be launched in the US by the end of 2016. CR is the controlled release proprietary 3:2 morphine/oxycodone formulation, encompassing both sustained delivery technology as well as abuse deterrent and tamper resistant features. IV is the intravenous variant, being developed as first line therapy for acute moderate to severe hospital-based administration. This formulation has completed a proof-of-concept Phase 2 trial.

After the first half results in which the company posted a $5.2 million loss, Citi noted the company had enough cash to fund the rest of its plans for 2013. The broker believes there is significant upside for the stock once MoxDuo is approved and retains a Buy rating. This is one of the three rating the stock on FNArena's database. The other two, JP Morgan and CIMB, also have Buy recommendations. The price targets diverge quite strongly, reflecting the large risks associated with biotech companies which have products up for scrutiny by health officials. Citi has set the top at $2.33 while JP Morgan has the lowest at $1.03. The consensus target of $1.72 suggests 40.1% upside to the last share price.

Bell Potter has a target of $2.30, recently raised from $1.10. The broker believes the current share price is undervaluing the stock's potential and maintains there's a strong possibility of a re-rating after the meeting scheduled with the FDA advisory committee in mid 2013. A response from the FDA is expected in the September quarter.





--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
plastic
post Posted: Jan 19 2013, 12:46 PM
  Quote Post


Posts: 10,988
Thanks: 315


More price pressure to the downside if the FDA stalls on the no precedent bit. Expect QRx to prevaricate a bit on this.

QRxPharma's Dual-Opioid Therapy MoxDuo Will Face FDA Cmte. Scrutiny


FDA told the company there is no precedent for reviewing a combination product that contains two drugs from the same class. The company's NDA resubmission for the morphine/oxycodone immediate-release product will include oxygen saturation data from a study originally conducted for European regulators.





--------------------
What did Uncle Mel do to us?
 
arty
post Posted: Jun 27 2012, 11:35 AM
  Quote Post


Posts: 13,078
Thanks: 3381


In Reply To: abner29's post @ Jun 27 2012, 09:10 AM

I take that as a "No"

Attached Image



some warning signs noticed in the lead-up:

Attached Image





--------------------
I trade daily, but I am not a licensed adviser. Whether you find my ideas reasonable or not: The only person responsible for your actions is YOU.
I follow two rules: (1) There are no sacred truths. All assumptions must be critically examined. Arguments from authority are worthless. (2) Whatever is inconsistent with observed facts must be discarded or revised. We must understand the Market as it is and not confuse how it is with how we wish it to be. (inspired by Carl Sagan)
 
 


6 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING